Copyright Reports & Markets. All rights reserved.

Global Cancer Monoclonal Antibodies Market Research Report 2019

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Cancer Monoclonal Antibodies Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Cancer Monoclonal Antibodies Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Cancer Monoclonal Antibodies Market Size Growth Rate by Type
    • 1.4.2 Murine Antibodies
    • 1.4.3 Chimeric and Humanised Antibodies
    • 1.4.4 Fully Humanized Antibodies
    • 1.4.5 Others
  • 1.5 Market by Application
    • 1.5.1 Global Cancer Monoclonal Antibodies Market Size Growth Rate by Application
    • 1.5.2 Liver
    • 1.5.3 Breast
    • 1.5.4 Blood
    • 1.5.5 Brain
    • 1.5.6 Hodgkins and Non-Hodgkins lymphoma
    • 1.5.7 Colorectal
    • 1.5.8 Leukaemia
    • 1.5.9 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Cancer Monoclonal Antibodies Market Size, Estimates and Forecasts
    • 2.1.1 Global Cancer Monoclonal Antibodies Revenue 2015-2026
    • 2.1.2 Global Cancer Monoclonal Antibodies Sales 2015-2026
  • 2.2 Global Cancer Monoclonal Antibodies, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Cancer Monoclonal Antibodies Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Cancer Monoclonal Antibodies Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Cancer Monoclonal Antibodies Competitor Landscape by Players

  • 3.1 Cancer Monoclonal Antibodies Sales by Manufacturers
    • 3.1.1 Cancer Monoclonal Antibodies Sales by Manufacturers (2015-2020)
    • 3.1.2 Cancer Monoclonal Antibodies Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Cancer Monoclonal Antibodies Revenue by Manufacturers
    • 3.2.1 Cancer Monoclonal Antibodies Revenue by Manufacturers (2015-2020)
    • 3.2.2 Cancer Monoclonal Antibodies Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Cancer Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibodies Revenue in 2019
    • 3.2.5 Global Cancer Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Cancer Monoclonal Antibodies Price by Manufacturers
  • 3.4 Cancer Monoclonal Antibodies Manufacturing Base Distribution, Product Types
    • 3.4.1 Cancer Monoclonal Antibodies Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Cancer Monoclonal Antibodies Product Type
    • 3.4.3 Date of International Manufacturers Enter into Cancer Monoclonal Antibodies Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Cancer Monoclonal Antibodies Market Size by Type (2015-2020)
    • 4.1.1 Global Cancer Monoclonal Antibodies Sales by Type (2015-2020)
    • 4.1.2 Global Cancer Monoclonal Antibodies Revenue by Type (2015-2020)
    • 4.1.3 Cancer Monoclonal Antibodies Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Cancer Monoclonal Antibodies Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Cancer Monoclonal Antibodies Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Cancer Monoclonal Antibodies Revenue Forecast by Type (2021-2026)
    • 4.2.3 Cancer Monoclonal Antibodies Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Cancer Monoclonal Antibodies Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Cancer Monoclonal Antibodies Market Size by Application (2015-2020)
    • 5.1.1 Global Cancer Monoclonal Antibodies Sales by Application (2015-2020)
    • 5.1.2 Global Cancer Monoclonal Antibodies Revenue by Application (2015-2020)
    • 5.1.3 Cancer Monoclonal Antibodies Price by Application (2015-2020)
  • 5.2 Cancer Monoclonal Antibodies Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Cancer Monoclonal Antibodies Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Cancer Monoclonal Antibodies Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Cancer Monoclonal Antibodies Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Cancer Monoclonal Antibodies by Country
    • 6.1.1 North America Cancer Monoclonal Antibodies Sales by Country
    • 6.1.2 North America Cancer Monoclonal Antibodies Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Cancer Monoclonal Antibodies Market Facts & Figures by Type
  • 6.3 North America Cancer Monoclonal Antibodies Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Cancer Monoclonal Antibodies by Country
    • 7.1.1 Europe Cancer Monoclonal Antibodies Sales by Country
    • 7.1.2 Europe Cancer Monoclonal Antibodies Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Cancer Monoclonal Antibodies Market Facts & Figures by Type
  • 7.3 Europe Cancer Monoclonal Antibodies Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Cancer Monoclonal Antibodies by Region
    • 8.1.1 Asia Pacific Cancer Monoclonal Antibodies Sales by Region
    • 8.1.2 Asia Pacific Cancer Monoclonal Antibodies Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Cancer Monoclonal Antibodies Market Facts & Figures by Type
  • 8.3 Asia Pacific Cancer Monoclonal Antibodies Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Cancer Monoclonal Antibodies by Country
    • 9.1.1 Latin America Cancer Monoclonal Antibodies Sales by Country
    • 9.1.2 Latin America Cancer Monoclonal Antibodies Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Cancer Monoclonal Antibodies Market Facts & Figures by Type
  • 9.3 Central & South America Cancer Monoclonal Antibodies Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Cancer Monoclonal Antibodies by Country
    • 10.1.1 Middle East and Africa Cancer Monoclonal Antibodies Sales by Country
    • 10.1.2 Middle East and Africa Cancer Monoclonal Antibodies Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Cancer Monoclonal Antibodies Market Facts & Figures by Type
  • 10.3 Middle East and Africa Cancer Monoclonal Antibodies Market Facts & Figures by Application

11 Company Profiles

  • 11.1 F. Hoffmann-La Roche
    • 11.1.1 F. Hoffmann-La Roche Corporation Information
    • 11.1.2 F. Hoffmann-La Roche Description and Business Overview
    • 11.1.3 F. Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Products Offered
    • 11.1.5 F. Hoffmann-La Roche Related Developments
  • 11.2 Amgen
    • 11.2.1 Amgen Corporation Information
    • 11.2.2 Amgen Description and Business Overview
    • 11.2.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Amgen Cancer Monoclonal Antibodies Products Offered
    • 11.2.5 Amgen Related Developments
  • 11.3 Bristol-Myers Squibb
    • 11.3.1 Bristol-Myers Squibb Corporation Information
    • 11.3.2 Bristol-Myers Squibb Description and Business Overview
    • 11.3.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Bristol-Myers Squibb Cancer Monoclonal Antibodies Products Offered
    • 11.3.5 Bristol-Myers Squibb Related Developments
  • 11.4 Takeda Pharmaceuticals
    • 11.4.1 Takeda Pharmaceuticals Corporation Information
    • 11.4.2 Takeda Pharmaceuticals Description and Business Overview
    • 11.4.3 Takeda Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Products Offered
    • 11.4.5 Takeda Pharmaceuticals Related Developments
  • 11.1 F. Hoffmann-La Roche
    • 11.1.1 F. Hoffmann-La Roche Corporation Information
    • 11.1.2 F. Hoffmann-La Roche Description and Business Overview
    • 11.1.3 F. Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Products Offered
    • 11.1.5 F. Hoffmann-La Roche Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Cancer Monoclonal Antibodies Market Estimates and Projections by Region
    • 12.1.1 Global Cancer Monoclonal Antibodies Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Cancer Monoclonal Antibodies Revenue Forecast by Regions 2021-2026
  • 12.2 North America Cancer Monoclonal Antibodies Market Size Forecast (2021-2026)
    • 12.2.1 North America: Cancer Monoclonal Antibodies Sales Forecast (2021-2026)
    • 12.2.2 North America: Cancer Monoclonal Antibodies Revenue Forecast (2021-2026)
    • 12.2.3 North America: Cancer Monoclonal Antibodies Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Cancer Monoclonal Antibodies Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Cancer Monoclonal Antibodies Sales Forecast (2021-2026)
    • 12.3.2 Europe: Cancer Monoclonal Antibodies Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Cancer Monoclonal Antibodies Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Cancer Monoclonal Antibodies Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Cancer Monoclonal Antibodies Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Cancer Monoclonal Antibodies Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Cancer Monoclonal Antibodies Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Cancer Monoclonal Antibodies Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Cancer Monoclonal Antibodies Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Cancer Monoclonal Antibodies Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Cancer Monoclonal Antibodies Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Cancer Monoclonal Antibodies Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Cancer Monoclonal Antibodies Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Cancer Monoclonal Antibodies Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Cancer Monoclonal Antibodies Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Cancer Monoclonal Antibodies Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Cancer Monoclonal Antibodies Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Cancer Monoclonal Antibodies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Monoclonal Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Cancer Monoclonal Antibodies market is segmented into
    Murine Antibodies
    Chimeric and Humanised Antibodies
    Fully Humanized Antibodies
    Others

    Segment by Application, the Cancer Monoclonal Antibodies market is segmented into
    Liver
    Breast
    Blood
    Brain
    Hodgkins and Non-Hodgkins lymphoma
    Colorectal
    Leukaemia
    Others

    Regional and Country-level Analysis
    The Cancer Monoclonal Antibodies market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Cancer Monoclonal Antibodies market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Cancer Monoclonal Antibodies Market Share Analysis
    Cancer Monoclonal Antibodies market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cancer Monoclonal Antibodies business, the date to enter into the Cancer Monoclonal Antibodies market, Cancer Monoclonal Antibodies product introduction, recent developments, etc.

    The major vendors covered:
    F. Hoffmann-La Roche
    Amgen
    Bristol-Myers Squibb
    Takeda Pharmaceuticals
    ...

    Buy now